Welcome to our dedicated page for Alumis news (Ticker: ALMS), a resource for investors and traders seeking the latest updates and insights on Alumis stock.
Alumis Inc. (Nasdaq: ALMS) is a late-stage biopharma and clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. The Alumis news feed on Stock Titan aggregates company press releases and market-moving updates so readers can review the latest disclosures directly from the issuer.
In its news releases, Alumis highlights progress across a pipeline centered on precision immunology. Key updates include clinical data and trial milestones for envudeucitinib (envu, formerly ESK-001), a next-generation, highly selective oral TYK2 inhibitor being studied in the Phase 3 ONWARD program for moderate-to-severe plaque psoriasis and the Phase 2b LUMUS trial in systemic lupus erythematosus. The company has reported positive topline Phase 3 results in plaque psoriasis and completion of enrollment in the LUMUS SLE study, along with prior Phase 2 data publications.
News items also cover advancement of A‑005, a potentially first‑in‑class fully CNS‑penetrant oral TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneous anti‑IGF‑1R therapy for thyroid eye disease that has received Fast Track Designation from the U.S. Food and Drug Administration, as described by Alumis. Corporate and financial announcements include quarterly financial results, guidance on cash runway, collaboration revenue from Kaken Pharmaceutical, participation in healthcare investor conferences, and details of the company’s merger with ACELYRIN, Inc.
Investors following ALMS news can use this page to review updates on public offerings of common stock conducted under Alumis’ shelf registration statement, regulatory and clinical milestones for its late-stage programs, and other operational developments described in its press releases. Bookmark this news feed to monitor how Alumis communicates clinical progress, capital markets activity and strategic initiatives related to its immune-mediated disease pipeline.
Alumis (Nasdaq: ALMS) reported Phase 3 ONWARD1 and ONWARD2 results for oral TYK2 inhibitor envudeucitinib, showing rapid, deep skin clearance and symptom relief. PASI 90 reached 68.0% and 62.1% at Week 24; PASI 100 reached 41.0% and 39.5% at Week 24.
Quality-of-life and itch improved early (DLQI ~50% at Week 12; >4-point itch improvement by Week 16). Safety was consistent with Phase 2. Alumis plans an NDA submission in H2 2026 and continues ONWARD3 extension.
Alumis (Nasdaq: ALMS) reported year-end 2025 results and clinical progress for envudeucitinib, highlighting positive Phase 3 ONWARD1/ONWARD2 topline results in moderate-to-severe plaque psoriasis with ~65% PASI 90 and >40% PASI 100 at Week 24.
The company closed an upsized public offering raising ~$345.1 million gross, held $308.5 million cash and expects to fund operations into Q4 2027; an NDA submission is planned in 2H 2026 and potential SLE Phase 2b topline data are anticipated in 3Q 2026.
Alumis (Nasdaq: ALMS) announced that Phase 3 ONWARD 1 and 2 results for envudeucitinib will be presented as a late‑breaking oral presentation at the 2026 AAD Annual Meeting on March 28, 2026, at 11:12 am MDT.
A Phase 2 STRIDE biomarker analysis will appear as an e‑poster (poster 73714). Alumis will host an investor webcast on March 29, 2026 at 5:00 pm MDT to review the ONWARD data; presentations and a replay will be posted on the company website on March 28–29, 2026.
Alumis (Nasdaq: ALMS) announced that CEO Martin Babler will speak at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET. A live webcast will be available on the company's Investors > Events page, and a replay will be archived for 90 days.
Alumis (Nasdaq: ALMS) will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook: Biotech Summit on February 11-12 in New York with a fireside chat on February 12 at 9:00 AM ET, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26 with a presentation on February 26 at 3:20 PM ET.
Live webcasts will be available on the company’s Investors > Events page, and replay archives will remain on the website for 90 days.
Alumis (Nasdaq: ALMS) closed an upsized underwritten public offering on January 9, 2026, selling 20,297,500 shares of common stock at $17.00 per share, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares. The gross proceeds to Alumis were approximately $345.1 million before underwriting discounts, commissions and offering expenses. All offered shares were sold by Alumis under a shelf registration on Form S-3 declared effective on August 19, 2025. Joint book-running managers and co-lead managers were named for the transaction. The company noted prospectus documents are available on the SEC website and from the listed managers.
Alumis (Nasdaq: ALMS) priced an upsized underwritten public offering of 17,650,000 shares at $17.00 per share, generating approximately $300.0 million in gross proceeds before fees. The company is selling all shares and granted the underwriters a 30-day option to buy up to an additional 2,647,500 shares at the public offering price, less discounts and commissions. The offering is expected to close on January 9, 2026, subject to customary closing conditions. The offering is being conducted under an SEC-declared effective shelf registration and will be documented in a final prospectus filed with the SEC.
Alumis (Nasdaq: ALMS) announced on January 6, 2026 its plan to commence an underwritten public offering of $175.0 million of common stock, with Alumis as the seller.
The company also expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares. The offering is subject to market and other conditions and may not be completed.
Joint book-running managers for the proposed offering are Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities. A preliminary prospectus supplement will be filed with the SEC and be available on sec.gov.
Alumis (Nasdaq: ALMS) reported positive topline Phase 3 results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis from ONWARD1 and ONWARD2.
Key highlights: across both trials PASI 75 74%, sPGA 0/1 59% at Week 16; at Week 24 ~65% PASI 90 and >40% PASI 100. Rapid separation from placebo on PASI 90 by Week 4. Envudeucitinib was superior to placebo and apremilast (p<0.0001) on primary endpoints. Safety through Week 24 was consistent with Phase 2; common TEAEs included headaches, nasopharyngitis, upper respiratory infections, and acne. Alumis plans an NDA submission in H2 2026 and will present additional data at a future medical meeting.
Alumis (Nasdaq: ALMS) will report topline results from the Phase 3 ONWARD program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026.
The company will host a conference call and webcast to discuss the topline data at 8:00 a.m. ET. Investors may access the live webcast via the company’s Investors > Events page at www.alumis.com. A replay of the webcast will be available on the company website after the call.